A Phase II Study of Nirogacestat in People with Recurrent Ovarian Granulosa Cell Tumors


Full Title

A Phase 2 Trial of Nirogacestat in Patients With Recurrent Ovarian Granulosa Cell Tumors


Ovarian granulosa cell tumors are a rare form of ovarian cancer. There is no standard therapy for patients with recurrent disease. In this study, researchers are evaluating the safety and effectiveness of the drug nirogacestat to treat people with ovarian granulosa cell tumors that have come back or continued to grow despite therapy.

Nirogacestat blocks a protein called gamma secretase, which plays a role in cancer cell growth and survival. By blocking this protein, nirogacestat may cause tumors to stop growing or shrink. Nirogacestat is taken orally (by mouth).


To be eligible for this study, patients must meet several requirements, including:

  • Participants must have an ovarian granulosa cell tumor that has come back or continued to grow despite treatment.
  • The serious side effects of previous therapies should go away before nirogacestat is given.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for people age 18 and older.


For more information and to ask about eligibility for this study, please contact the office of Dr. Rachel Grisham at 646-888-4653.





Disease Status

Relapsed or Refractory